Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Travere Therapeutics (TVTX)

April 14, 2026 6:47 AM EDT Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $47.00 price target on Travere Therapeutics (NASDAQ: TVTX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login